Current stock page

Catalysts

NKTR Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

NKTRNektar Therapeutics

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 1/10
$37.27+$0.02 (+0.05%)

Latest quote

  • Momentum
    25
  • Value
    47
  • Quality
    49
  • Risk resilience
    41
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 2, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 39/100

Momentum 25/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 6.14%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 25/100AIQ Edge 1/10 Relative Laggard
Beat rate
75%
6 of 8 reported periods
Average surprise
+52.4%
Across covered historical reports
Latest result
+21.3%
Nov 12, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 12, 2026—-$2.07-$1.63+21.3%$10.27M$9.39M
Aug 13, 2026—-$1.97-$1.23+37.6%$10.43M$10.13M
May 7, 2026—-$1.58-$1.82-15.0%$10.69M$10.86M
Mar 12, 2026—-$2.47-$1.78+28.1%$10.19M$21.81M
Nov 6, 2025—-$2.85-$1.85+35.1%$10.05M$11.79M
Aug 7, 2025—-$3.03-$2.95+2.6%$9.49M$11.18M
May 8, 2025—-$2.56-$3.60-40.4%$15.35M$10.46M
Mar 12, 2025—-$0.18$0.45+350.0%$35.5M$29.18M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
11
Buy
4
Hold
12-month analyst target
$95.75
+156.91% versus current price
Based on 15 analyst observations. Targets are estimates, not predictions.
Low target
$50.00
+34.16% vs latest price
Average target
$95.75
+156.91% vs latest price
High target
$150.00
+302.47% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 2, 2027

Next known earnings or reporting date.

EPS estimate-$2.76

Current analyst expectation for the upcoming report.

Revenue estimate$10.47M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score25

Where event reaction would show up first.

AIQ score39/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
15
Average target
$95.75
Target upside
156.91%
Target range
$50.00 - $150.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
0
Negative
2
seekingalpha.com · Nov 13, 2026

Nektar Therapeutics (NKTR) Q3 2026 Earnings Call Transcript

Nektar Therapeutics (NKTR) Q3 2026 Earnings Call November 12, 2026 5:00 PM ESTCompany ParticipantsVivian Wu - Investor RelationsHoward W.

zacks.com · Nov 12, 2026

Nektar Therapeutics (NKTR) Reports Q3 Loss, Lags Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of +24.54% and -8.85%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

gurufocus.com · Oct 12, 2026

Leerink Highlights Nektar Therapeutics (NKTR) as Top Emerging Tech Pick Ahead of Rezpegaldesleukin Phase 3 Data

On October 12, 2026, Leerink Partners identified Nektar Therapeutics (NASDAQ: NKTR) as a leading choice in the emerging technology sector, spotlighting its inno

insidermonkey.com · Oct 7, 2026

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

Michigan-based investment advisor Cedar Grove Capital Management recently released its third-quarter 2026 investor letter. The letter can be downloaded here.

investors.com · Oct 1, 2026

Nektar Therapeutics Stock Tumbles Despite Long-Term Benefit From Alopecia Drug

Nektar Therapeutics stock took a hit Thursday despite test results that suggested its drug has long-term benefits for alopecia patients.

Open full news and sentiment

NKTR Catalysts FAQ

What are the next catalysts for NKTR stock?

NKTR's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move NKTR stock?

Upcoming events that could move NKTR include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could NKTR's next earnings report affect the stock?

NKTR's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive NKTR stock higher?

NKTR could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt NKTR stock?

NKTR could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.